Tecentriq®

Active substance

atezolizumab

Holder

Roche

Status

closed

Indication

adjuvant treatment following resection and platinum‐based chemotherapy for adult patients with stage IIB‐III non‐small cell lung cancer (NSCLC) whose tumours have PD‐L1 expression on ≥50% of tumour cells (AL43776).

Public documents

Approbation

Information for the patient

Informed consent

Last update

11/08/2022